EnteroMedics Inc  

(Public, NASDAQ:ETRM)   Watch this stock  
Find more results for ETRM
-3.28 (-36.85%)
After Hours: 5.60 -0.02 (-0.36%)
Jan 18, 7:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.45 - 7.20
52 week 1.75 - 132.30
Open 6.72
Vol / Avg. 11.00M/4.84M
Mkt cap 8.72M
P/E     -
Div/yield     -
EPS -178.40
Shares 2.39M
Beta 2.10
Inst. own 7%
Feb 15, 2017
Q4 2016 EnteroMedics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 30, 2016
EnteroMedics Inc Commercial and Corporate Update Corporate Call
Nov 10, 2016
Q3 2016 EnteroMedics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -2197.89% -8732.45%
Operating margin -1504.53% -9543.42%
EBITD margin - -9478.83%
Return on average assets -204.67% -196.35%
Return on average equity - -493.31%
Employees 37 -
CDP Score - -


2800 Patton Rd
SAINT PAUL, MN 55113-1100
United States - Map
+1-651-6343003 (Phone)
+1-651-6343212 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Officers and directors

Dan W. Gladney Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Scott P. Youngstrom Chief Financial Officer, Chief Compliance Officer
Age: 56
Bio & Compensation  - Reuters
Nick Ansari Senior Vice President - Sales
Age: 54
Bio & Compensation  - Reuters
Paul Hickey Senior Vice President - Marketing and Reimbursement
Age: 51
Bio & Compensation  - Reuters
Peter M Delange Senior Vice President - Operations and Business Development
Age: 46
Bio & Compensation  - Reuters
Adrianus Donders Senior Vice President - Research and Advanced Development
Age: 61
Bio & Compensation  - Reuters
Katherine S. Tweden Ph.D. Senior Vice President - Research
Age: 54
Bio & Compensation  - Reuters
Tonya Dowd Vice President - Reimbursement
Bio & Compensation  - Reuters
Gary D. Blackford Director
Age: 59
Bio & Compensation  - Reuters
Lori Courtney McDougal Director
Bio & Compensation  - Reuters